SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of ...
Genomic testing firm Veracyte Inc., of South San Francisco, has inked a definitive agreement with Seattle-based Nanostring Technologies Inc. for the global rights to Nanostring’s Ncounter platform.
NanoString Technologies, Inc. announced the launch of a Single Cell Gene Expression application that provides researchers with a flexible and highly sensitive approach to discovering differences in ...
A comparison of the burden of thyroid cancer amongst European Union 15+ countries, 1990-2017: Estimates from the Global Burden of Disease Study. This is an ASCO Meeting Abstract from the 2021 ASCO ...
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s ...
NanoString Technologies, Inc. a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results